Detecting cancer has traditionally relied on invasive tissue biopsies, usually performed when imaging techniques like ultrasounds or CT scans reveal suspicious cell growth. Standard procedures involve guiding a needle into the affected organ to extract tissue samples. When cancer develops deep inside internal organs beyond the reach of a needle, minor surgeries become necessary. These rigorous diagnostic procedures ultimately confirm whether a patient has cancer, but they typically occur only after the disease has advanced significantly. However, ongoing medical experiments are evaluating tests capable of identifying cancer in its earliest stages, with liquid biopsy emerging as a primary focus. Dr. Ravi Shankar, a senior consultant and oral cancer specialist at Max Hospital, details how this innovative method functions.
Understanding Liquid Biopsy and Its Mechanism
Dr. Ravi Shankar explains that liquid biopsy involves detecting cancer through blood or other bodily fluids. Instead of relying on physical tissue removal, a patient's blood or fluid sample undergoes thorough analysis to check for circulating tumor cells, commonly referred to as CTCs, or their remnants. Traditional biopsies require extracting flesh via needles or surgical incisions, creating a painful and complex experience. In contrast, liquid biopsy requires only a simple blood draw or fluid sample, using it to trace the DNA of cancer cells without making a single cut.
The Role of Circulating Tumor Cells in Blood
When cancer cells multiply in any part of the body, some of these cells inevitably die or break apart. These microscopic fragments and the DNA released from them enter the bloodstream, circulating throughout the body. Medical science terms these particles circulating tumor cells or ctDNA. Because these fragments float freely within the blood, specialized machinery can successfully detect and identify them when a patient's blood sample is processed in a laboratory setting.
Monitoring Patients Undergoing or Following Treatment
Dr. Shankar highlights that advanced liquid biopsy tests prove particularly exceptional for patients currently undergoing cancer treatment or those who have already completed their therapy. Most cancer survivors face the persistent threat of recurrence. Advanced liquid biopsy helps clinicians maintain rigorous surveillance over these individuals. Conventional methods like CT scans or standard biopsies sometimes fail to detect returning cancer early, delaying necessary interventions. However, if a liquid biopsy detects circulating tumor cells, it indicates that microscopic cancer cells remain active within the bloodstream, potentially triggering a future relapse.
Guiding Additional Therapies and Risk Reduction
The presence of circulating tumor cells at a microscopic level signals to doctors that proactive measures are necessary. Consequently, physicians may recommend administering additional cycles of chemotherapy or maintenance therapy. This approach substantially diminishes the risk of cancer progression. Although highly promising, clinical protocols continue to evaluate its broader implementation.
Current Status and Future Outlook
Dr. Ravi Shankar clarifies that liquid biopsy is not yet universally accepted as a definitive standalone method for confirming cancer, nor does it currently form part of standard medical protocols. Nevertheless, numerous ongoing studies continue yielding positive indicators. If future research progresses favorably, this technique could establish a robust foundation for early cancer identification, potentially serving as a monumental milestone in oncology. Ultimately, its widespread adoption remains contingent upon forthcoming scientific findings and continued validation.
